PE20220590A1 - Agonistas del receptor del peptido-1 similar al glucagon - Google Patents
Agonistas del receptor del peptido-1 similar al glucagonInfo
- Publication number
- PE20220590A1 PE20220590A1 PE2021002176A PE2021002176A PE20220590A1 PE 20220590 A1 PE20220590 A1 PE 20220590A1 PE 2021002176 A PE2021002176 A PE 2021002176A PE 2021002176 A PE2021002176 A PE 2021002176A PE 20220590 A1 PE20220590 A1 PE 20220590A1
- Authority
- PE
- Peru
- Prior art keywords
- glucagon
- peptide
- receptor agonists
- compound
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Referido a compuesto seleccionado entre I, II, II y IV. Estos compuestos son agonistas del receptor del peptido-1 similar al glucagon. Tambien se refiere a metodos de preparacion de dicho compuesto, una composicion farmaceutica que comprende dicho compuesto, y su uso en el tratamiento de la diabetes mellitus tipo II.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962868117P | 2019-06-28 | 2019-06-28 | |
US201962904906P | 2019-09-24 | 2019-09-24 | |
PCT/US2020/038617 WO2020263695A1 (en) | 2019-06-28 | 2020-06-19 | Glucagon-like peptide 1 receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20220590A1 true PE20220590A1 (es) | 2022-04-22 |
Family
ID=71575804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021002176A PE20220590A1 (es) | 2019-06-28 | 2020-06-19 | Agonistas del receptor del peptido-1 similar al glucagon |
Country Status (31)
Country | Link |
---|---|
US (2) | US11655242B2 (es) |
EP (2) | EP4302826A3 (es) |
JP (1) | JP7256300B2 (es) |
KR (1) | KR20220012924A (es) |
CN (1) | CN114008033A (es) |
AU (1) | AU2020309064B2 (es) |
CA (1) | CA3144055C (es) |
CL (1) | CL2021003419A1 (es) |
CO (1) | CO2021017433A2 (es) |
CR (1) | CR20210599A (es) |
DK (1) | DK3989972T3 (es) |
DO (1) | DOP2021000273A (es) |
EC (1) | ECSP21093576A (es) |
ES (1) | ES2970173T3 (es) |
FI (1) | FI3989972T3 (es) |
HR (1) | HRP20231586T1 (es) |
HU (1) | HUE065080T2 (es) |
IL (1) | IL288479A (es) |
JO (1) | JOP20210337A1 (es) |
LT (1) | LT3989972T (es) |
MD (1) | MD3989972T2 (es) |
MX (1) | MX2021015328A (es) |
PE (1) | PE20220590A1 (es) |
PL (1) | PL3989972T3 (es) |
PT (1) | PT3989972T (es) |
RS (1) | RS64940B1 (es) |
SA (1) | SA521431209B1 (es) |
SI (1) | SI3989972T1 (es) |
TW (1) | TWI751585B (es) |
WO (1) | WO2020263695A1 (es) |
ZA (1) | ZA202109587B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
BR112022007627A2 (pt) | 2019-10-25 | 2022-07-12 | Gilead Sciences Inc | Compostos moduladores do glp-1r |
CN114761395A (zh) * | 2019-12-02 | 2022-07-15 | 现代药品株式会社 | Glp-1受体激动剂 |
KR20220156535A (ko) | 2020-02-07 | 2022-11-25 | 가셔브룸 바이오, 인크. | 헤테로사이클릭 glp-1 작용제 |
US20230165846A1 (en) * | 2020-02-13 | 2023-06-01 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
KR102563111B1 (ko) * | 2020-03-18 | 2023-08-04 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
TWI825398B (zh) * | 2020-03-18 | 2023-12-11 | 南韓商Lg化學股份有限公司 | Glp-1 受體促效劑、包含該促效劑之醫藥組成物及其製備方法 |
CN116323599A (zh) | 2020-08-06 | 2023-06-23 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
EP4204415A1 (en) | 2020-08-28 | 2023-07-05 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
CA3200245A1 (en) * | 2020-11-27 | 2022-06-02 | Junjun Wu | Benzimidazole derivative and preparation method therefor and medical use thereof |
WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
WO2022202864A1 (ja) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | 縮合環を有するglp-1受容体作動薬を含有する医薬組成物 |
US20240300928A1 (en) * | 2021-04-08 | 2024-09-12 | Lg Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
US11858918B2 (en) | 2021-04-21 | 2024-01-02 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
MX2023012918A (es) * | 2021-05-03 | 2024-03-13 | Carmot Therapeutics Inc | Agonistas del receptor del péptido 1 similar al glucagón (glp-1) de bencimidazoilo, composiciones farmacéuticas que los comprenden y métodos para su uso. |
TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
WO2023038039A1 (ja) | 2021-09-08 | 2023-03-16 | 塩野義製薬株式会社 | 抗肥満作用の関与する疾患の予防及び治療用医薬 |
WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
KR20240073108A (ko) | 2021-10-05 | 2024-05-24 | 아스트라제네카 아베 | Glp-1 수용체 조절제로서의 특정 2,5-디아자바이시클로[4.2.0]옥탄 |
WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
AU2023232184A1 (en) | 2022-03-08 | 2024-09-26 | Guangzhou Apichope Pharmaceutical Co., Ltd. | Benzo bicyclic compound, and preparation method and application thereof |
WO2024041609A1 (zh) * | 2022-08-24 | 2024-02-29 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120053180A1 (en) * | 2010-08-27 | 2012-03-01 | Chemizon, A Division Of Optomagic Co., Ltd. | Cyclohexane analogues as gpr119 agonists |
TWI537262B (zh) * | 2011-08-17 | 2016-06-11 | 美國禮來大藥廠 | 供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物 |
WO2018098781A1 (en) * | 2016-12-01 | 2018-06-07 | Eli Lilly And Company | Pyrrolidinone compounds |
PL3555064T3 (pl) * | 2016-12-16 | 2023-03-06 | Pfizer Inc. | Agoności receptora GLP-1 i ich zastosowania |
TWI707683B (zh) * | 2018-06-13 | 2020-10-21 | 美商輝瑞股份有限公司 | Glp-1受體促效劑及其用途 |
WO2019239371A1 (en) | 2018-06-15 | 2019-12-19 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
KR20210106447A (ko) * | 2018-11-22 | 2021-08-30 | 치루 레고르 테라퓨틱스 인코포레이티드 | Glp-1r 효능제 및 그의 용도 |
KR20210152513A (ko) * | 2019-04-12 | 2021-12-15 | 치루 레고르 테라퓨틱스 인코포레이티드 | Glp-1r 작용제 및 이의 용도 |
US10954221B2 (en) * | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
WO2021018023A1 (zh) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
BR112022007627A2 (pt) * | 2019-10-25 | 2022-07-12 | Gilead Sciences Inc | Compostos moduladores do glp-1r |
BR112022009287A2 (pt) | 2019-11-15 | 2022-08-09 | Ildong Pharmaceutical Co Ltd | Agonista do receptor de glp-1 e uso do mesmo |
CN114761395A (zh) | 2019-12-02 | 2022-07-15 | 现代药品株式会社 | Glp-1受体激动剂 |
EP4097097A1 (en) | 2020-01-29 | 2022-12-07 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
US20230165846A1 (en) | 2020-02-13 | 2023-06-01 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
TWI825398B (zh) * | 2020-03-18 | 2023-12-11 | 南韓商Lg化學股份有限公司 | Glp-1 受體促效劑、包含該促效劑之醫藥組成物及其製備方法 |
TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
US20230295154A1 (en) | 2020-04-29 | 2023-09-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
-
2020
- 2020-06-17 TW TW109120333A patent/TWI751585B/zh active
- 2020-06-19 SI SI202030314T patent/SI3989972T1/sl unknown
- 2020-06-19 PL PL20739523.7T patent/PL3989972T3/pl unknown
- 2020-06-19 PT PT207395237T patent/PT3989972T/pt unknown
- 2020-06-19 RS RS20231184A patent/RS64940B1/sr unknown
- 2020-06-19 MX MX2021015328A patent/MX2021015328A/es unknown
- 2020-06-19 KR KR1020217042363A patent/KR20220012924A/ko not_active Application Discontinuation
- 2020-06-19 JO JOP/2021/0337A patent/JOP20210337A1/ar unknown
- 2020-06-19 DK DK20739523.7T patent/DK3989972T3/da active
- 2020-06-19 PE PE2021002176A patent/PE20220590A1/es unknown
- 2020-06-19 HU HUE20739523A patent/HUE065080T2/hu unknown
- 2020-06-19 CN CN202080046428.3A patent/CN114008033A/zh active Pending
- 2020-06-19 HR HRP20231586TT patent/HRP20231586T1/hr unknown
- 2020-06-19 FI FIEP20739523.7T patent/FI3989972T3/fi active
- 2020-06-19 JP JP2021577551A patent/JP7256300B2/ja active Active
- 2020-06-19 US US16/906,063 patent/US11655242B2/en active Active
- 2020-06-19 AU AU2020309064A patent/AU2020309064B2/en active Active
- 2020-06-19 EP EP23206307.3A patent/EP4302826A3/en active Pending
- 2020-06-19 MD MDE20220509T patent/MD3989972T2/ro unknown
- 2020-06-19 CR CR20210599A patent/CR20210599A/es unknown
- 2020-06-19 WO PCT/US2020/038617 patent/WO2020263695A1/en active Application Filing
- 2020-06-19 EP EP20739523.7A patent/EP3989972B1/en active Active
- 2020-06-19 ES ES20739523T patent/ES2970173T3/es active Active
- 2020-06-19 LT LTEPPCT/US2020/038617T patent/LT3989972T/lt unknown
- 2020-06-19 CA CA3144055A patent/CA3144055C/en active Active
-
2021
- 2021-11-25 ZA ZA2021/09587A patent/ZA202109587B/en unknown
- 2021-11-28 IL IL288479A patent/IL288479A/en unknown
- 2021-12-20 CO CONC2021/0017433A patent/CO2021017433A2/es unknown
- 2021-12-20 CL CL2021003419A patent/CL2021003419A1/es unknown
- 2021-12-23 DO DO2021000273A patent/DOP2021000273A/es unknown
- 2021-12-26 SA SA521431209A patent/SA521431209B1/ar unknown
- 2021-12-28 EC ECSENADI202193576A patent/ECSP21093576A/es unknown
-
2023
- 2023-03-31 US US18/194,155 patent/US20230250092A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20220590A1 (es) | Agonistas del receptor del peptido-1 similar al glucagon | |
CL2017001760A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
ECSP21004913A (es) | Compuestos coagonistas de gip/glp1 | |
PE20210162A1 (es) | Analogos de incretina y sus usos | |
ZA202007304B (en) | Glp-1 receptor agonists and uses thereof | |
CO2019005924A2 (es) | Agonistas duales acilados de glp-1/glp-2 | |
CL2019001465A1 (es) | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip. | |
NZ740644A (en) | Glucagon receptor agonists | |
GT201500049A (es) | Proteinas de fusiòn para el tratamiento de un sìndrome metàbolico | |
PE20150900A1 (es) | Derivados de exendida-4 como agonistas duales de glp1/glucagon | |
PE20170087A1 (es) | Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon | |
AR099977A1 (es) | Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4 | |
AR069136A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos | |
CL2012002635A1 (es) | Péptido que presenta actividad para el receptor del péptido insulinotrópico dependiente de glucosa (gip-r) y para el receptor del péptido-1 similar al glucagón (glp-1-r) y son selectivos sobre el receptor del glucagón (gluc-r); formulación farmacéutica que lo comprende; y su uso para el tratamiento de diabetes mellitus y para la pérdida de peso. | |
ES2687651T3 (es) | Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos | |
DOP2006000219A (es) | Indoles de acilo, composiciones que contienen dichos compuestos y procedimientos de uso | |
EA201170302A1 (ru) | Процессированные аналоги глюкозозависимого инсулинотропного полипетида | |
AR105284A1 (es) | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
CL2020002574A1 (es) | Análogos novedosos de glp-1 | |
CL2011002182A1 (es) | Compuestos heterociclicos que contienen 2 o mas heterociclos con n como heteroatomos del ciclo, agonistas de gpr119 e inhibidores de dpp-iv; composicion farmaceutica; y su uso en el tratamiento de la diabetes tipo ii, obesidad, sindrome metabolico, tolerancia deteriorada a la glucosa e hiperlipidemia, entre otras enfermedades.. | |
CL2022001724A1 (es) | Método y aplicación de preparación de compuesto como agente de degradación de proteínas | |
CL2017002913A1 (es) | Tratamiento de la hipoglucemia posbariátrica con exendina (9-39) | |
PE20150607A1 (es) | Composicion farmaceutica que comprende fimasartan e hidroclorotiazida | |
ECSP23095307A (es) | Agonista del receptor de glp-1 y composición y uso del mismo | |
EA202192296A1 (ru) | Терапевтическое применение дулаглутида |